A TERRA-NONO axis drives fibroblast reprogramming in cancer
Science Advances · 2026
DOI: 10.1126/sciadv.aed3358 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Emery Di Cicco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Cellular Reprogramming, Cancer-Associated Fibroblasts, Neoplasms. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NCI NIH HHS, NIH Clinical Center.
Abstract (Originalsprache)
The molecular mechanisms linking chromosome homeostasis to fibroblast reprogramming into cancer-associated fibroblasts (CAFs) remain poorly understood. Here, we identify a clinically relevant, telomere-associated nuclear pathway driving CAF activation across multiple human cancers. The long noncoding RNA TERRA is consistently elevated in CAFs from skin, lung, and breast tumors. We show that the androgen receptor (AR) represses TERRA transcription through subtelomeric binding, and its loss enables TERRA up-regulation and interaction with the RNA binding protein NONO. This interaction forms a CAF-specific nuclear complex that reprograms gene expression. Mechanistically, NONO is directly recruited to and binds the promoters of key CAF effector genes, where it regulates their transcription in a TERRA-dependent manner. Disrupting the TERRA-NONO axis, via TERRA silencing or pharmacologic NONO inhibition, reverses CAF activation and suppresses tumor-stroma interactions in vitro and in vivo, highlighting its therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
- Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
- Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
- International Cancer Prevention Institute, Epalinges, Switzerland.
ORCID-Profile: Emery Di Cicco, Jovan Isma, Stefano Sol, Gaetana Restivo, Luigi Mazzeo, Atul Katarkar, Sandro Goruppi, Joni Renee White, Juerg Hafner, Anna Mandinova, Gian Paolo Dotto
Förderung
- NIAMS NIH HHS
- NCI NIH HHS
- NIH Clinical Center
- Dermatology Foundation
- Fondazione AIRC per la ricerca sul cancro ETS
- H2020 Marie SkÅodowska-Curie Actions
Zitieren
APA
Di Cicco, E., Isma, J., Sol, S., Restivo, G., Mazzeo, L., Katarkar, A., Goruppi, S., White, J. R., Hafner, J., Neel, V. A., Mandinova, A., Levesque, M. P., & Dotto, G. P. (2026). A TERRA-NONO axis drives fibroblast reprogramming in cancer. Science Advances. https://doi.org/10.1126/sciadv.aed3358
Vancouver
Di Cicco E, Isma J, Sol S, Restivo G, Mazzeo L, Katarkar A, et al. A TERRA-NONO axis drives fibroblast reprogramming in cancer. Science Advances. 2026. doi:10.1126/sciadv.aed3358
BibTeX
@article{DiCicco2026,
author = {Di Cicco, Emery and Isma, Jovan and Sol, Stefano and Restivo, Gaetana and Mazzeo, Luigi and Katarkar, Atul and Goruppi, Sandro and White, Joni Renee and Hafner, Juerg and Neel, Victor A and Mandinova, Anna and Levesque, Mitchell P and Dotto, Gian Paolo},
title = {A TERRA-NONO axis drives fibroblast reprogramming in cancer},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aed3358}
}
EUVIMED